Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efineptakin alfa - Genexine

Drug Profile

Efineptakin alfa - Genexine

Alternative Names: GX 17; GX-I7; HyLeukin; HyLeukin-7™; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT-17; Recombinant human IL-7-hyFc; rhIL-7-hyFc; TJ 107

Latest Information Update: 04 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Genexine; I-MAB Biopharma; Merck & Co; NeoImmuneTech
  • Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 7 replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic CD4-positive T-lymphocytopenia; Progressive multifocal leukoencephalopathy
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Glioblastoma; Skin cancer; Solid tumours
  • Phase I COVID 2019 infections; Idiopathic CD4-positive T-lymphocytopenia
  • Preclinical Human papillomavirus infections; Lymphoma
  • No development reported Cervical intraepithelial neoplasia

Most Recent Events

  • 31 Aug 2020 I-MAB Biopharma plans a phase II trial for Glioblastoma in China in the fourth quarter of 2020
  • 24 Aug 2020 US FDA approves IND application for combination of efineptakin alfa and tisagenlecleucel in B cell lymphoma
  • 24 Aug 2020 NeoImmuneTech plans a phase Ib trial for B cell lymphoma (Second-line therapy or greater, Combination therapy)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top